Clear Route, year 2
The new year means that the Hambrecht & Quist Life Sciences Conference is upon us once again, launching the next 12 months of attempts by companies to persuade the Street to pay attention, because this time, by George, we've really figured it out.
While we would like to see the end of the tower of BioBabel, experience tells us not to expect the kinds of stories demanded by the investment community. And, while we also hope this is not true, we would expect many of these now-predictable presentations to turn away those investors who still linger by the sector. Like the Democrats, biotech companies have the stern task